Lys-MDA explained

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1] [2] [3] [4] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[5]

See also

Notes and References

  1. Web site: MindMed announces Phase 1 study of MDMA-like substances. . Buntz B . Drug Discovery and Development . 21 September 2022 .
  2. Web site: MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances. . Biospace.com . 20 September 2022 .
  3. Novel Safrylamine derivatives having prodrug properties. . Grill M . 17 March 2022 . Compass Pathfinder Limited . WO . 2022/053696 . . .
  4. Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof . Clark S, Duncton MA . Terran Biosciences Inc . 12 January 2023 . WO . 2023/283373 . . .
  5. Web site: ClinicalTrials.gov . ClinicalTrials.gov . 13 November 2024.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lys-MDA".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.